### IAP12 Rec'd PCT/PTO 1 6 JUN 2006

INFORMATION DISCLOSURE

**STATEMENT** 

Patent Application

Docket No. ARS-128

June 16, 2006

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Christine Power, Amanda Proudfoot, Achim Frauenschuh

Filed

June 16, 2006

For

**CC-Chemokine Binding Tick Proteins** 

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

#### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

## 10/583218

# IAP12 Rec'd PCT/PTO 16 JUN 2006

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO INFORMATION DISCLOSURE						Con	nplete if Known	
						Application Number		
						Filing Date	June 16, 2006	
STATEMENT BY APPLICANT						First Named Inventor	Christine Power	
	(u	se as many sheel	s as nec	essary)		Art Unit		
						Examiner Name		
	Sheet	1	of	2		Attorney Docket Number	ARS-128	

U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. 1 Document Number Number - Kind Code <sup>2</sup> (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	U1	US-2003/050244 A1	03-13-2003	Fuchsberger et al.	All				
	U2	US-							
	U3	US-	(i) (i)	,					
	U4	US-							
	Ų5	US-							
	U6	US-							
	U7	US-							
	U8	US-							
	U9	US-							

		FOREIGN	PATENT DOCU	JMENTS		
.,		Foreign Patent Document	5 1 11 11 11 15 15	Name of Batantas as	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 01/78770 A1	10-25-2001	The Regents of the University of California	All	
	F2	WO 00/27873	05-18-2000	Research Corporation Technologies, Inc.	All	
	F3					<u> </u>
•	F4	·				
•	F5					
	F6					

Examiner	Date	
Signature	 Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP901.04. Enter Office that issued the document, by the two-letter code (WPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## 10/583218 IAP12 Rec'd PCT/PTO 1 6 JUN 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

	Substitute for form 1449B/PTO INFORMATION DISCLOSURE					Complete if Known		
						Application Number		
						Filing Date	June 16, 2006	
	STATEMENT BY APPLICANT					First Named Inventor	Christine Power	
	fue	o ac many chao	e oc noce	accond)	•	Group Art Unit	·	
	(use as many sheets as necessary)					Examiner Name		
	Sheet	2	of	•	2	Attorney Docket Number	ARS-128	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	DATABASE EMBL "Putative 8.9 kDa secreted protein" October 1, 2002, XP002330449, ACCESSION NO. Q8MVA1, abstract.	
	R2	DATABASE EMBL 'Online! "Danio rerio genomic clone DKEY-12P12, genomic survey sequence" June 6, 2002, XP002330450, ACCESSION NO. AL737166, abstract.	
	R3	DATABASE EMBL "Putative 9.4 kDa secreted protein from Ixodes scapularis" October 1, 2002, XP002295520, ACCESSION NO. Q8MVA2, abstract.	
	R4	HAJNICKA, V. et al. "Anti-Interleukin-8 activity of tick salivary gland extracts" Parasite Immunology, 2001, pp 483-489, Vol. 23, No. 9.	
	R5	KOCAKOVA, P. et al. "Effect of fast protein liquid chromatography fractionated salivary gland extracts from different ixodid tick species on interleukin-8 binding to its cell receptors" Folia Parasitologica, March 2003, pp. 79-84, Vol. 50, No. 1.	
	R6	VALENZUELA, J. G. "Exploring the messages of the salivary glands of <i>ixodes ricinus</i> " <i>Am. J. Trop. Med. Hyg.</i> , 2002, pp. 223-224, Vol. 66, No. 3.	
	R7	KOVAR, L. et al. "Salivary gland extract from <i>Ixodes ricinus</i> tick modulates the host immune response towards the Th2 cytokine profile" <i>Parasitol. Res.</i> , December 2002, pp. 1066-1072, Vol. 88, No. 12.	
	R8	ANGUITA, J. et al. "Salp15, an lxodes scapularis salivary protein, inhibits CD4 <sup>+</sup> T cell activation" Immunity, June 2002, pp. 849-859, Vol. 16, No. 6.	
	R9		
	R10		
	R11		
	R12		

Examiner					Date	
Signature		_ : : : : : : : : : : : : : : : : : : :		<u> </u>	Considered	·
EVALUATED. Inter-	.,	and described to the state of the same	4 - 4 - 41 1 - 1 - 1	24 14050 44		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 
Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.